![3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/docs/US/2019-10-22/US10450284B2/abs.jpg.600x600.jpg)
- Patent Title: 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
-
Application No.: US16220041Application Date: 2018-12-14
-
Publication No.: US10450284B2Publication Date: 2019-10-22
- Inventor: Xiaozhang Zheng , Pui Yee Ng , Bingsong Han , Jennifer R. Thomason , Mary-Margaret Zablocki , Cuixian Liu , Aleksandra Rudnitskaya , David R. Lancia, Jr. , David S. Millan , Matthew W. Martin
- Applicant: FORMA Therapeutics, Inc.
- Applicant Address: US MA Watertown
- Assignee: Forma Therapeutics, Inc.
- Current Assignee: Forma Therapeutics, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Choate, Hall & Stewart LLP
- Agent Michael A. Shinall; Erica M. D'Amato
- Main IPC: A61K31/553
- IPC: A61K31/553 ; C07D498/04 ; C07D267/14 ; C07D413/06 ; C07D413/12 ; C07D413/04 ; C07D243/14 ; C07D291/08 ; C07D401/06 ; C07D401/10 ; C07D403/06 ; C07D403/10 ; C07D405/06 ; C07D413/14 ; C07D417/04 ; C07D471/04 ; C07D498/08 ; C07D493/08 ; C07D413/08 ; C07D491/107 ; C07D495/10 ; C07D267/12
![3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors](/abs-image/US/2019/10/22/US10450284B2/abs.jpg.150x150.jpg)
Abstract:
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
Public/Granted literature
- US20190119232A1 3-ARYL-4-AMIDO-BICYCLIC [4,5,0] HYDROXAMIC ACIDS AS HDAC INHIBITORS Public/Granted day:2019-04-25
Information query
IPC分类:
